Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ZYME

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday.

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks Inc. (NASDAQ:ZYME) on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Zymeworks in Focus for Insider Activity: Catalysts Ahead

Zymeworks' insider EcoR1 Capital is buying shares ahead of expected catalysts in 2025 that could drive the stock price to multiyear highs.

3 Biotech Stocks With Potential to Be Big Winners in 2023

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

Biotech companies are on track to stay resilient amid a potential economic slowdown due to their inelastic demand and continued breakthroughs. Therefore, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), United Therapeutics (UTHR), and Jazz Pharmaceuticals (JAZZ). On the other hand, Bionano Genomics (BNGO)…

5 Biotech Stocks That Could Make You Rich in 10 Years

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Get in on Before It’s Too Late

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

3 Biotech Stocks to Help Boost Your Portfolio in January

3 Biotech Stocks to Help Boost Your Portfolio in January

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

2 Biotech Stock to Buy Over Moderna This December

2 Biotech Stock to Buy Over Moderna This December

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

3 Stocks Downgraded to "Strong Sell" This Week

3 Stocks Downgraded to "Strong Sell" This Week

Deepening of yield curve inversion on speculations about the Fed’s future rate hikes and weaker-than-expected economic data from some influential nations are expected to keep the stock market under pressure. Amid the uncertainties surrounding the market, it could be wise to avoid fundamentally weak stocks Zymeworks (ZYME), Volcon (VLCN), and…

Zymeworks Turns Down All Blue's Hostile Bid

Zymeworks Turns Down All Blue's Hostile Bid

Zymeworks Inc's (NYSE: ZYME) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons.

Where Zymeworks Stands With Analysts

Where Zymeworks Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Zymeworks: Q4 Earnings Insights

Zymeworks: Q4 Earnings Insights

Zymeworks (NYSE:ZYME) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Zymeworks beat estimated earnings by 16.67%, reporting an EPS of $-0.95 versus an estimate of $-1.14.

Get all your
news in one place.

100’s of premium titles.
One news app.

A Preview Of Zymeworks's Earnings

Zymeworks (NYSE:ZYME) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Zymeworks will report an earnings per share (EPS) of $-1.14.

Zymeworks Raises $100M Via Equity Issued At 14% Discount

Zymeworks Inc (NYSE: ZYME) has priced its underwritten public offering of 9.16 million common shares, pre-funded warrants to purchase up to 3.34 million shares.

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities

Zymeworks Inc (NYSE: ZYME) said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team would be leaving the Company.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

B of A Securities

Gilead Sciences Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

340,552 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play